Inmune Bio Stock Performance
| INMB Stock | USD 8.04 0.09 1.13% |
On a scale of 0 to 100, INmune Bio holds a performance score of 11. The company retains a Market Volatility (i.e., Beta) of 0.67, which attests to possible diversification benefits within a given portfolio. As returns on the market increase, INmune Bio's returns are expected to increase less than the market. However, during the bear market, the loss of holding INmune Bio is expected to be smaller as well. Please check INmune Bio's total risk alpha, downside variance, daily balance of power, as well as the relationship between the maximum drawdown and skewness , to make a quick decision on whether INmune Bio's current trending patterns will revert.
Risk-Adjusted Performance
Good
Weak | Strong |
Compared to the overall equity markets, risk-adjusted returns on investments in INmune Bio are ranked lower than 11 (%) of all global equities and portfolios over the last 90 days. Despite somewhat weak primary indicators, INmune Bio sustained solid returns over the last few months and may actually be approaching a breakup point. ...more
Actual Historical Performance (%)
One Day Return (0.87) | Five Day Return (2.57) | Year To Date Return 61.26 | Ten Year Return (0.50) | All Time Return (0.50) |
1 | Acquisition by Allen Marcia of 32500 shares of INmune Bio at 5.05 subject to Rule 16b-3 | 12/20/2024 |
2 | Acquisition by Lowdell Mark William of 14423 shares of INmune Bio at 8.32 subject to Rule 16b-3 | 12/31/2024 |
3 | Acquisition by Moss David J of 160000 shares of INmune Bio at 9.92 subject to Rule 16b-3 | 01/24/2025 |
4 | INmune Bio Rating Increased to Strong-Buy at RODMANRENSHAW - MarketBeat | 01/29/2025 |
5 | Acquisition by Xencor Inc of 192533 shares of INmune Bio at 17.14 subject to Rule 16b-3 | 01/30/2025 |
6 | Acquisition by Schroeder Timothy J of 12500 shares of INmune Bio at 9.92 subject to Rule 16b-3 | 01/31/2025 |
7 | Why INmune Bio Inc Is Skyrocketing So Far In 2025 - Yahoo Finance | 02/03/2025 |
8 | Why INmune Bio Inc Is Skyrocketing So Far In 2025 | 02/04/2025 |
9 | INmune Bio Announces Plan to Submit FDA Biologics License Application Seeking Approval of CORDStrom for Treatment of Recessive Dystrophic Epidermolysis Bullosa | 02/10/2025 |
10 | INmune Bio Opens Phase II in High Dose Cohort of INKmune Trial in Prostate Cancer | 02/12/2025 |
11 | Acquisition by Baracchini Edgardo Jr of 35000 shares of INmune Bio subject to Rule 16b-3 | 03/05/2025 |
12 | Acquisition by Lowdell Mark William of 140000 shares of INmune Bio at 5.05 subject to Rule 16b-3 | 03/07/2025 |
| Begin Period Cash Flow | 52.2 M | |
| Free Cash Flow | -12 M |
INmune |
INmune Bio Relative Risk vs. Return Landscape
If you would invest 525.00 in INmune Bio on December 11, 2024 and sell it today you would earn a total of 279.00 from holding INmune Bio or generate 53.14% return on investment over 90 days. INmune Bio is currently generating 0.8897% in daily expected returns and assumes 6.1072% risk (volatility on return distribution) over the 90 days horizon. In different words, 54% of stocks are less volatile than INmune, and 83% of all traded equity instruments are projected to make higher returns than the company over the 90 days investment horizon. Expected Return |
| Risk |
INmune Bio Market Risk Analysis
Today, many novice investors tend to focus exclusively on investment returns with little concern for INmune Bio's investment risk. Standard deviation is the most common way to measure market volatility of stocks, such as INmune Bio, and traders can use it to determine the average amount a INmune Bio's price has deviated from the expected return over a period of time. It is calculated by determining the expected price for the established period and then subtracting this figure from each price point. The differences are then squared, summed, and averaged to produce the variance.
Sharpe Ratio = 0.1457
| Best Portfolio | Best Equity | |||
| Good Returns | ||||
| Average Returns | ||||
| Small Returns | INMB | |||
| Cash | Small Risk | Average Risk | High Risk | Huge Risk |
| Negative Returns |
Estimated Market Risk
| 6.11 actual daily | 54 54% of assets are less volatile |
Expected Return
| 0.89 actual daily | 17 83% of assets have higher returns |
Risk-Adjusted Return
| 0.15 actual daily | 11 89% of assets perform better |
Based on monthly moving average INmune Bio is performing at about 11% of its full potential. If added to a well diversified portfolio the total return can be enhanced and market risk can be reduced. You can increase risk-adjusted return of INmune Bio by adding it to a well-diversified portfolio.
INmune Bio Fundamentals Growth
INmune Stock prices reflect investors' perceptions of the future prospects and financial health of INmune Bio, and INmune Bio fundamentals are critical determinants of its market performance. Overall, investors pay close attention to revenue and earnings growth, profit margins, and debt levels. These fundamentals can have a significant impact on INmune Stock performance.
| Return On Equity | -0.99 | ||||
| Return On Asset | -0.45 | ||||
| Operating Margin | (989.21) % | ||||
| Current Valuation | 147.18 M | ||||
| Shares Outstanding | 22.17 M | ||||
| Price To Earning | (7.51) X | ||||
| Price To Book | 4.60 X | ||||
| Price To Sales | 4,234 X | ||||
| Revenue | 155 K | ||||
| Gross Profit | 42 K | ||||
| EBITDA | (29.74 M) | ||||
| Net Income | (30.01 M) | ||||
| Cash And Equivalents | 61.21 M | ||||
| Cash Per Share | 3.41 X | ||||
| Total Debt | 10.44 M | ||||
| Debt To Equity | 0.22 % | ||||
| Current Ratio | 30.87 X | ||||
| Book Value Per Share | 1.74 X | ||||
| Cash Flow From Operations | (11.98 M) | ||||
| Earnings Per Share | (2.18) X | ||||
| Market Capitalization | 177.82 M | ||||
| Total Asset | 57 M | ||||
| Retained Earnings | (121.02 M) | ||||
| Working Capital | 21.48 M | ||||
| Current Asset | 8.38 M | ||||
| Current Liabilities | 721.01 K | ||||
About INmune Bio Performance
By analyzing INmune Bio's fundamental ratios, stakeholders can gain valuable insights into INmune Bio's financial health, operational efficiency, and overall profitability, helping them make informed investment and management decisions. For instance, if INmune Bio has a high ROA and ROE, it suggests that the company is efficiently using its assets and equity to generate substantial profits, making it an attractive investment. Conversely, if INmune Bio has a low ROA and ROE, it may indicate underlying issues in asset and equity management, signaling a need for operational improvements.
| Last Reported | Projected for Next Year | ||
| Return On Tangible Assets | (0.67) | (0.70) | |
| Return On Capital Employed | (0.89) | (0.84) | |
| Return On Assets | (0.47) | (0.50) | |
| Return On Equity | (0.90) | (0.86) |
Things to note about INmune Bio performance evaluation
Checking the ongoing alerts about INmune Bio for important developments is a great way to find new opportunities for your next move. Stock alerts and notifications screener for INmune Bio help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.| INmune Bio is way too risky over 90 days horizon | |
| INmune Bio appears to be risky and price may revert if volatility continues | |
| The company reported the previous year's revenue of 155 K. Net Loss for the year was (30.01 M) with profit before overhead, payroll, taxes, and interest of 42 K. | |
| INmune Bio currently holds about 61.21 M in cash with (11.98 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 3.41. | |
| INmune Bio has a frail financial position based on the latest SEC disclosures | |
| Roughly 31.0% of the company shares are held by company insiders | |
| Latest headline from finance.yahoo.com: INmune Bio Opens Phase II in High Dose Cohort of INKmune Trial in Prostate Cancer |
- Analyzing INmune Bio's financial statements, including its income statement, balance sheet, and cash flow statement, helps in understanding its overall financial health and growth potential.
- Getting a closer look at valuation ratios like price-to-earnings (P/E) ratio, price-to-sales (P/S) ratio, and price-to-book (P/B) ratio help in understanding whether INmune Bio's stock is overvalued or undervalued compared to its peers.
- Examining INmune Bio's industry or sector and how it is performing can give you an idea of its growth potential and how it is positioned relative to its competitors.
- Evaluating INmune Bio's management team can have a significant impact on its success or failure. Reviewing the track record and experience of INmune Bio's management team can help you assess the Company's leadership.
- Pay attention to analyst opinions and ratings of INmune Bio's stock. These opinions can provide insight into INmune Bio's potential for growth and whether the stock is currently undervalued or overvalued.
Complementary Tools for INmune Stock analysis
When running INmune Bio's price analysis, check to measure INmune Bio's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy INmune Bio is operating at the current time. Most of INmune Bio's value examination focuses on studying past and present price action to predict the probability of INmune Bio's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move INmune Bio's price. Additionally, you may evaluate how the addition of INmune Bio to your portfolios can decrease your overall portfolio volatility.
| ETF Categories List of ETF categories grouped based on various criteria, such as the investment strategy or type of investments | |
| Correlation Analysis Reduce portfolio risk simply by holding instruments which are not perfectly correlated | |
| Portfolio Optimization Compute new portfolio that will generate highest expected return given your specified tolerance for risk | |
| Portfolio Comparator Compare the composition, asset allocations and performance of any two portfolios in your account |